Brent A Neuschwander-Tetri
Overview
Explore the profile of Brent A Neuschwander-Tetri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
12220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stefan N, Yki-Jarvinen H, Neuschwander-Tetri B
Lancet Diabetes Endocrinol
. 2024 Dec;
13(2):134-148.
PMID: 39681121
The global epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide. People with MASLD can progress to cirrhosis and hepatocellular carcinoma and are at increased risk of developing...
2.
Jain A, Busgang S, Gennings C, Yates K, Schwimmer J, Rosenthal P, et al.
J Pediatr Gastroenterol Nutr
. 2024 Sep;
79(5):943-953.
PMID: 39282813
Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in children. We hypothesized environmental toxins could drive progression to metabolic dysfunction-associated steatohepatitis (MASH), and assayed serum toxins and metabolites in...
3.
Huang D, Wilson L, Behling C, Amangurbanova M, Kleiner D, Kowdley K, et al.
Hepatology
. 2024 Jul;
PMID: 39028908
Background And Aims: There are limited data on the progression of liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) in people with type 2 diabetes mellitus (T2DM) versus those...
4.
Gawrieh S, Vilar-Gomez E, Wilson L, Pike F, Kleiner D, Neuschwander-Tetri B, et al.
J Hepatol
. 2024 May;
81(4):600-608.
PMID: 38762169
Background & Aims: The clinical significance of change in liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) in patients with non-alcoholic fatty liver disease (NAFLD) is not well-understood. We...
5.
Chalasani N, Vilar-Gomez E, Loomba R, Yates K, Diehl A, Neuschwander-Tetri B, et al.
Hepatology
. 2024 Apr;
80(5):1212-1226.
PMID: 38652636
Background And Aims: The patatin-like phospholipase domain-containing protein 3 ( PNPLA3 ) rs738409 variant is associated with steatotic liver disease and its progression. We examined the association between PNPLA3 and...
6.
Barritt 4th A, Yu F, Mospan A, Newsome P, Roden M, Morris H, et al.
Am J Gastroenterol
. 2024 Apr;
119(8):1624-1627.
PMID: 38587293
Introduction: This study investigates the applicability of the new metabolic dysfunction-associated steatotic liver disease (MASLD) nomenclature to the real-world TARGET-NASH US adult cohort. Methods: The new MASLD/metabolic steatohepatitis nomenclature was...
7.
Kanwal F, Neuschwander-Tetri B, Loomba R, Rinella M
Hepatology
. 2024 Mar;
79(5):1212-1219.
PMID: 38445559
This commentary discusses how clinicians and various stakeholders can utilize the recently published American Association for the Study of Liver Diseases nonalcoholic fatty liver disease (AASLD NAFLD) Practice Guidance in...
8.
Jain A, Buchannan P, Yates K, Belt P, Schwimmer J, Rosenthal P, et al.
Hepatol Commun
. 2023 Dec;
7(12).
PMID: 38055641
Background: Pediatric metabolic-associated fatty liver disease (MAFLD) is a global health problem, with lifestyle modification as its major therapeutic strategy. Rigorous characterization of dietary content on MAFLD in children is...
9.
Kitsugi K, Noritake H, Matsumoto M, Hanaoka T, Umemura M, Yamashita M, et al.
Mol Cell Biochem
. 2023 Oct;
479(10):2697-2710.
PMID: 37902885
Background & Aims: Hepatic stellate cells (HSCs) play an essential role in liver fibrogenesis. The induction of cellular senescence has been reported to inhibit HSC activation. Previously, we demonstrated that...
10.
Mukherjee S, Chakraborty M, Msengi E, Haubner J, Zhang J, Jellinek M, et al.
Mol Metab
. 2023 Jul;
75:101767.
PMID: 37429524
Objective: Defining the regulators of cell metabolism and signaling is essential to design new therapeutic strategies in obesity and NAFLD/NASH. E3 ubiquitin ligases control diverse cellular functions by ubiquitination-mediated regulation...